Utama › Jangkitan Adenoviridae › Ohio
Kajian klinikal Jangkitan Adenoviridae di Ohio
7 kajian untuk Jangkitan Adenoviridae sedang mencari peserta di lokasi di Ohio.
Bandar di Ohio
Teks kajian rasmi (Bahasa Inggeris)
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
- Nationwide Children's Hospital, Columbus
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
Umur 1 hingga 85 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT03665675Donor-Derived Viral Specific T-cells (VSTs)
- Akron Children's Hospital, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
Mengambil pesertaFasa 1/2
4 Weeks · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02048332Third Party Viral Specific T-cells (VSTs)
- Akron Children's Hospital, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus
Mengambil pesertaFasa 2
2 Days · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02532452A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- University of Cincinnati Cancer Center, Cincinnati
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07544589A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
- Cincinnati Children's Hospital, Cincinnati
- Nationwide Children's Hospital, Columbus
Mengambil pesertaFasa 3
2 Months · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07387367Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
- Nationwide Children's Hosptial, Columbus
Mengambil pesertaFasa 2
1 Month – 79 Years · Semua jantina · Dikemas kini 8 Ogo 2025 · NCT03266627Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
- Nationwide Children's Hospital, Columbus
Mengambil pesertaFasa 1/2
Sehingga umur 60 · Semua jantina · Dikemas kini 13 Mei 2025 · NCT04722029Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.